This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Dividendos de Abiomed

Dividendo controles de criterios 0/6

Información clave

n/a

Rentabilidad por dividendo

n/a

Ratio de pago

Rentabilidad media de la industria	1.8%
Próxima fecha de pago de dividendos	n/a
Fecha ex dividendo	n/a
Dividendo por acción	n/a
Beneficios por acción	US$5.91
Rentabilidad por dividendo prevista a 3 años	n/a

Últimas actualizaciones de dividendos

No hay actualizaciones

Recent updates

Abiomed's Less Troubled 2020 Justifies Multiple, But Medium-Term Headwinds Mean Capital Risk

Jan 24

The Returns At Abiomed (NASDAQ:ABMD) Aren't Growing

Jan 04

These 4 Measures Indicate That Abiomed (NASDAQ:ABMD) Is Using Debt Safely

Dec 14

Abiomed: Impella Will Continue To Drive Revenue Growth

Sep 10

Here's What To Make Of Abiomed's (NASDAQ:ABMD) Decelerating Rates Of Return

Sep 01

Abiomed: Recovery Mode Has Been Activated - Reiterate Buy Rating

Jul 13

At US$335, Is It Time To Put Abiomed, Inc. (NASDAQ:ABMD) On Your Watch List?

Jul 08

DSMB recommends Abiomed trial for heart pump in cardiogenic shock continue

Jun 08

Abiomed acquires preCARDIA a company targeting acute heart failure

Jun 01

Here's Why I Think Abiomed (NASDAQ:ABMD) Might Deserve Your Attention Today

May 16

Boston Scientific’s new clinical trial can impact Abiomed: Raymond James

May 06

Abiomed FQ4 2021 Earnings Preview

Apr 28

Should You Investigate Abiomed, Inc. (NASDAQ:ABMD) At US$315?

Apr 02

Abiomed, Inc.'s (NASDAQ:ABMD) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Mar 12

Has Abiomed (NASDAQ:ABMD) Got What It Takes To Become A Multi-Bagger?

Feb 18

Results: Abiomed, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Jan 31

Estabilidad y crecimiento de los pagos

Obteniendo datos sobre dividendos

Dividendo estable: Insufficient data to determine if ABMD's dividends per share have been stable in the past.

Dividendo creciente: Insufficient data to determine if ABMD's dividend payments have been increasing.

Rentabilidad por dividendo vs. Mercado

Rentabilidad por dividendo de Abiomed vs. Mercado

¿Cómo se compara la rentabilidad por dividendo de ABMD con la del mercado?
Segmento	Rentabilidad por dividendo
Empresa (ABMD)	n/a
Suelo de mercado 25% (US)	1.5%
Techo de mercado 25% (US)	4.7%
Media de la industria (Medical Equipment)	1.8%
Previsión de analistas en 3 años (ABMD)	n/a

Dividendo destacado: Unable to evaluate ABMD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

Alto dividendo: Unable to evaluate ABMD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Pago de beneficios a los accionistas

Cobertura de los beneficios: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Pago en efectivo a los accionistas

Cobertura de flujo de caja: Unable to calculate sustainability of dividends as ABMD has not reported any payouts.

This company has been acquired

Dividendos de Abiomed

Dividendo controles de criterios 0/6

Información clave

Últimas actualizaciones de dividendos

Recent updates

Johnson & Johnson (NYSE:JNJ) completed the acquisition of Abiomed, Inc. (NasdaqGS:ABMD).

Abiomed Announces United States Food and Drug Administration Approves Version of Impella ECP

Abiomed, Inc.(NasdaqGS:ABMD) dropped from FTSE All-World Index (USD)

Abiomed, Inc. Announces First Patients in the World Treated with Impella Rp Flex with Smartassist

Price target increased to US$362

Independent Director notifies of intention to sell stock

Executive VP notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Johnson & Johnson (NYSE:JNJ) entered into a definitive agreement to acquire Abiomed, Inc. (NasdaqGS:ABMD) for $17.4 billion.

Impella RP Flex with SmartAssist Receives FDA Approval to Treat Right Heart Failure

Abiomed (NASDAQ:ABMD) Has More To Do To Multiply In Value Going Forward

Abiomed, Inc. Successfully Completes All Impella Post-Approval Studies for High-Risk PCI, Cardiogenic Shock, Post-Cardiotomy Cardiogenic Shock and Right Heart Failure

The United States Food and Drug Administration Grants 510(k) Clearance for Impella Low Profile Sheath

Abiomed's Impella low profile sheath gets FDA clearance

Abiomed, Inc. to Report Q2, 2023 Results on Nov 01, 2022

Price target decreased to US$313

Abiomed: Correction Offers Good Buying Opportunity

Abiomed Announces Two Approvals from the U.S. Food and Drug Administration Related to Clinical Research of Impella Heart Pumps in Acute Myocardial Infarction Cardiogenic Shock Patients

U.S. FDA gives two approvals to Abiomed Impella heart pumps

What Does Abiomed, Inc.'s (NASDAQ:ABMD) Share Price Indicate?

Abiomed Announces Restore EF Study Shows Heart Function, Symptom Improvements for High-Risk PCI Patients Supported by Impella

First quarter 2023 earnings: EPS exceeds analyst expectations

Abiomed, Inc. (NasdaqGS:ABMD) announces an Equity Buyback for $200 million worth of its shares.

Price target decreased to US$319

Abiomed FQ1 2023 Earnings Preview

Abiomed, Inc. to Report Q1, 2023 Results on Aug 04, 2022

Returns On Capital At Abiomed (NASDAQ:ABMD) Have Stalled

Abiomed, Inc., Annual General Meeting, Aug 10, 2022

Abiomed's Profit Growth Slows On R&D, Sales Hold Strong Despite Shortages

Full year 2022 earnings: EPS exceeds analyst expectations

Abiomed, Inc. to Report Q4, 2022 Results on Apr 28, 2022

Abiomed, Inc. Announces Retirement of David Weber as Senior Vice President, Chief Operating Officer

Is Abiomed (NASDAQ:ABMD) A Risky Investment?

Independent Director recently sold US$1.2m worth of stock

Senior VP & COO exercised options and sold US$3.1m worth of stock

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Abiomed, Inc. Revises Revenue Guidance for the Fiscal Year 2022

Consensus forecasts updated

Abiomed's Less Troubled 2020 Justifies Multiple, But Medium-Term Headwinds Mean Capital Risk

Early Feasibility Study Demonstrates Successful Use of Abiomed’s preCARDIA Technology

Abiomed, Inc. Announces Regulators Grants Approvals for Impella Surgical Products

The Returns At Abiomed (NASDAQ:ABMD) Aren't Growing

These 4 Measures Indicate That Abiomed (NASDAQ:ABMD) Is Using Debt Safely

Abiomed, Inc. (NasdaqGS:ABMD) agreed to acquire all the assets and business from Sensera, Inc. for $7.5 million.

Independent Director recently sold US$5.1m worth of stock

Second quarter 2022 earnings released: EPS US$1.25 (vs US$1.38 in 2Q 2021)

Abiomed: Impella Will Continue To Drive Revenue Growth

Here's What To Make Of Abiomed's (NASDAQ:ABMD) Decelerating Rates Of Return

Independent Director notifies of intention to sell stock

Consensus forecasts updated

Chairman exercised options and sold US$8.0m worth of stock

First quarter 2022 earnings released: EPS US$1.38 (vs US$0.99 in 1Q 2021)

Abiomed: Recovery Mode Has Been Activated - Reiterate Buy Rating

At US$335, Is It Time To Put Abiomed, Inc. (NASDAQ:ABMD) On Your Watch List?

Abiomed’s Receives U.S. Food and Drug Administration Pre-Market Approval as Safe and Effective to Treat Acute Right Heart Failure for Up to 14 Days

Chairman exercised options and sold US$7.6m worth of stock

DSMB recommends Abiomed trial for heart pump in cardiogenic shock continue

Abiomed, Inc. (NasdaqGS:ABMD) acquired Precardia Inc.

Abiomed acquires preCARDIA a company targeting acute heart failure

Full year 2021 earnings released: EPS US$5.00 (vs US$4.49 in FY 2020)

Here's Why I Think Abiomed (NASDAQ:ABMD) Might Deserve Your Attention Today

Senior VP & COO exercised options and sold US$3.7m worth of stock

Boston Scientific’s new clinical trial can impact Abiomed: Raymond James

Full year 2021 earnings released: EPS US$5.00 (vs US$4.49 in FY 2020)

Abiomed, Inc. Provides Earnings Guidance for the Fiscal Year 2022

Abiomed FQ4 2021 Earnings Preview

Should You Investigate Abiomed, Inc. (NASDAQ:ABMD) At US$315?

Abiomed, Inc.'s (NASDAQ:ABMD) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Abiomed Appoints of Myron L. Rolle to its Board of Directors

Has Abiomed (NASDAQ:ABMD) Got What It Takes To Become A Multi-Bagger?

VP & Chief Commercial Officer exercised options and sold US$1.5m worth of stock

Results: Abiomed, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Third quarter 2021 earnings released: EPS US$1.37 (vs US$1.53 in 3Q 2020)